255 related articles for article (PubMed ID: 24292706)
1. IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients.
Sim GC; Martin-Orozco N; Jin L; Yang Y; Wu S; Washington E; Sanders D; Lacey C; Wang Y; Vence L; Hwu P; Radvanyi L
J Clin Invest; 2014 Jan; 124(1):99-110. PubMed ID: 24292706
[TBL] [Abstract][Full Text] [Related]
2. Murine regulatory T cells contain hyperproliferative and death-prone subsets with differential ICOS expression.
Chen Y; Shen S; Gorentla BK; Gao J; Zhong XP
J Immunol; 2012 Feb; 188(4):1698-707. PubMed ID: 22231701
[TBL] [Abstract][Full Text] [Related]
3. Tumor-infiltrating mast cells stimulate ICOS
Lv Y; Tian W; Teng Y; Wang P; Zhao Y; Li Z; Tang S; Chen W; Xie R; Lü M; Zhuang Y
J Adv Res; 2024 Mar; 57():149-162. PubMed ID: 37086778
[TBL] [Abstract][Full Text] [Related]
4. CD4
Zhang S; Goswami S; Ma J; Meng L; Wang Y; Zhu F; Zhang D; Zheng S; Dong R; Xiao X; Zhang X; Chen G
Front Pediatr; 2019; 7():279. PubMed ID: 31355166
[TBL] [Abstract][Full Text] [Related]
5. Sex-specific differences in ICOS
Wu L; Kälble F; Lorenz HM; Zeier M; Schaier M; Steinborn A
Clin Exp Med; 2024 Mar; 24(1):47. PubMed ID: 38427068
[TBL] [Abstract][Full Text] [Related]
6. Augmenting TCR signal strength and ICOS costimulation results in metabolically fit and therapeutically potent human CAR Th17 cells.
Wyatt MM; Huff LW; Nelson MH; Neal LR; Medvec AR; Rangel Rivera GO; Smith AS; Rivera Reyes AM; Knochelmann HM; Riley JL; Lesinski GB; Paulos CM
Mol Ther; 2023 Jul; 31(7):2120-2131. PubMed ID: 37081789
[TBL] [Abstract][Full Text] [Related]
7. Attenuated IL-2 muteins leverage the TCR signal to enhance regulatory T cell homeostasis and response
Ma S; So M; Ghelani A; Srivas R; Sahoo A; Hall R; Liu W; Wu H; Yu S; Lu S; Song E; Cariaga T; Soto M; Zhou H; Li CM; Chaudhry A; Luo X; Sohn SJ
Front Immunol; 2023; 14():1257652. PubMed ID: 37809101
[TBL] [Abstract][Full Text] [Related]
8. Design of cyclic peptides as novel inhibitors of ICOS/ICOSL interaction.
Abdel-Rahman SA; Santini BL; Calvo-Barreiro L; Zacharias M; Gabr M
Bioorg Med Chem Lett; 2024 Feb; 99():129599. PubMed ID: 38185345
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-37 is highly expressed in regulatory T cells of melanoma patients and enhanced by melanoma cell secretome.
Osborne DG; Domenico J; Luo Y; Reid AL; Amato C; Zhai Z; Gao D; Ziman M; Dinarello CA; Robinson WA; Fujita M
Mol Carcinog; 2019 Sep; 58(9):1670-1679. PubMed ID: 31099111
[TBL] [Abstract][Full Text] [Related]
10. Interruption of the Intratumor CD8:Treg Crosstalk Improves the Efficacy of PD-1 Immunotherapy.
Geels SN; Moshensky A; Sousa RS; Walker BL; Singh R; Gutierrez G; Hwang M; Mempel TR; Nie Q; Othy S; Marangoni F
bioRxiv; 2023 May; ():. PubMed ID: 37292782
[TBL] [Abstract][Full Text] [Related]
11. Life-extended glycosylated IL-2 promotes Treg induction and suppression of autoimmunity.
Ottolenghi A; Bolel P; Sarkar R; Greenshpan Y; Iraqi M; Ghosh S; Bhattacharya B; Taylor ZV; Kundu K; Radinsky O; Gazit R; Stepensky D; Apte RN; Voronov E; Porgador A
Sci Rep; 2021 Apr; 11(1):7676. PubMed ID: 33828163
[TBL] [Abstract][Full Text] [Related]
12. IL-35 Therapy Boosts Treg in Transplantation.
Baydoun H; Camirand G
Transplantation; 2024 Jan; 108(1):14-15. PubMed ID: 37464475
[No Abstract] [Full Text] [Related]
13. The CD28-B7 Family in Anti-Tumor Immunity: Emerging Concepts in Cancer Immunotherapy.
Leung J; Suh WK
Immune Netw; 2014 Dec; 14(6):265-76. PubMed ID: 25550693
[TBL] [Abstract][Full Text] [Related]
14. High and interrelated rates of PD-L1+CD14+ antigen-presenting cells and regulatory T cells mark the microenvironment of metastatic lymph nodes from patients with cervical cancer.
Heeren AM; Koster BD; Samuels S; Ferns DM; Chondronasiou D; Kenter GG; Jordanova ES; de Gruijl TD
Cancer Immunol Res; 2015 Jan; 3(1):48-58. PubMed ID: 25361854
[TBL] [Abstract][Full Text] [Related]
15. Reducing CD73 expression by IL1β-Programmed Th17 cells improves immunotherapeutic control of tumors.
Chatterjee S; Thyagarajan K; Kesarwani P; Song JH; Soloshchenko M; Fu J; Bailey SR; Vasu C; Kraft AS; Paulos CM; Yu XZ; Mehrotra S
Cancer Res; 2014 Nov; 74(21):6048-59. PubMed ID: 25205101
[TBL] [Abstract][Full Text] [Related]
16. Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor.
Mittal D; Young A; Stannard K; Yong M; Teng MW; Allard B; Stagg J; Smyth MJ
Cancer Res; 2014 Jul; 74(14):3652-8. PubMed ID: 24986517
[TBL] [Abstract][Full Text] [Related]
17. Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer.
Allard B; Turcotte M; Stagg J
Expert Opin Ther Targets; 2014 Aug; 18(8):863-81. PubMed ID: 24798880
[TBL] [Abstract][Full Text] [Related]
18. Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model.
Iannone R; Miele L; Maiolino P; Pinto A; Morello S
Am J Cancer Res; 2014; 4(2):172-81. PubMed ID: 24660106
[TBL] [Abstract][Full Text] [Related]
19. Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion.
Häusler SF; Del Barrio IM; Diessner J; Stein RG; Strohschein J; Hönig A; Dietl J; Wischhusen J
Am J Transl Res; 2014; 6(2):129-39. PubMed ID: 24489992
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of CD73 stimulates the migration and invasion of B16F10 melanoma cells in vitro, but results in impaired angiogenesis and reduced melanoma growth in vivo.
Koszałka P; Pryszlak A; Gołuńska M; Kolasa J; Stasiłojć G; Składanowski AC; Bigda JJ
Oncol Rep; 2014 Feb; 31(2):819-27. PubMed ID: 24297662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
